

AMENDMENTS TO THE CLAIMS

1. (Currently amended) A method of ~~preventing and/or treating a chronic and/or an atopic skin disease~~ psoriasis by administering ~~an inhibitor of fatty acid oxidation~~ 2-(6-(4-chlorophenoxy)hexyl)oxirane-2-carboxylic acid ethyl ester (Etomoxir) to a patient in a pharmacologically effective amount.
2. (Original) The method according to claim 1, wherein the patient is human.
- 3.-16. (Canceled).
17. (Previously presented) The method according to claim 1, wherein said inhibitor is administered topically.
- 18.-19. (Canceled).
20. (Previously presented) The method according to claim 1, wherein the inhibitor is administered together with at least one excipient and/ or auxiliary.
21. (Original) The method according to claim 20, wherein the excipient and/or auxiliary is selected from the group consisting of one or more suitable adjuvant(s), one or more pharmaceutically active and/or acceptable carrier(s), diluent(s), filler(s), binder(s), disintegrant(s), lubricant(s), glident(s), coloring agent(s), flavoring agent(s), opaquing agent(s) and plasticizer(s).
22. (Currently amended) The method according to claim 20, wherein the inhibitor is administered topically and ~~preferably~~ the said at least one excipient

and/ or auxiliary is hydrophobic and is preferably selected from the group comprising consisting of petroleum jelly, wax, oleyl alcohol, propylene glycol monostearate, propylene glycol monopalmitostearate, isopropyl laureate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, ethyl myristate, propyl myristate, butyl myristate, ethyl oleate, Cetylstearyl alcohol, ~~Vaseline~~, lanolin alcohol ~~or~~ and paraffin oil.

23.- 47. (Canceled).